| pubmed-article:11488774 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0042960 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0024554 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C1549078 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C1997894 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0599874 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0851347 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0244104 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0043906 | lld:lifeskim |
| pubmed-article:11488774 | lifeskim:mentions | umls-concept:C0968699 | lld:lifeskim |
| pubmed-article:11488774 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:11488774 | pubmed:dateCreated | 2001-8-7 | lld:pubmed |
| pubmed-article:11488774 | pubmed:abstractText | NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione (2-(4-methylsulphonyl-2-nitrobenzoyl)-1,3-cyclohexanedione) are inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD). NTBC has been successfully used as a treatment for hereditary tyrosinaemia type 1 (HT-1), while mesotrione has been developed as an herbicide. The pharmacokinetics of the two compounds were investigated in healthy male volunteers following single oral administration. The aim of the NTBC study was to assess the bioequivalence of two different formulations and to determine the extent of the induced tyrosinaemia. The mesotrione study was performed to determine the magnitude and duration of the effect on tyrosine catabolism. Additionally, the urinary excretion of unchanged mesotrione was measured to assess the importance of this route of clearance and to help develop a strategy for monitoring occupational exposure. | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11488774 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11488774 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11488774 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:11488774 | pubmed:issn | 0306-5251 | lld:pubmed |
| pubmed-article:11488774 | pubmed:author | pubmed-author:LumholtzBB | lld:pubmed |
| pubmed-article:11488774 | pubmed:author | pubmed-author:EksborgSS | lld:pubmed |
| pubmed-article:11488774 | pubmed:author | pubmed-author:GuooJ YJY | lld:pubmed |
| pubmed-article:11488774 | pubmed:author | pubmed-author:WilksM FMF | lld:pubmed |
| pubmed-article:11488774 | pubmed:author | pubmed-author:ProvanW MWM | lld:pubmed |
| pubmed-article:11488774 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11488774 | pubmed:volume | 52 | lld:pubmed |
| pubmed-article:11488774 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11488774 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11488774 | pubmed:pagination | 169-77 | lld:pubmed |
| pubmed-article:11488774 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:meshHeading | pubmed-meshheading:11488774... | lld:pubmed |
| pubmed-article:11488774 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11488774 | pubmed:articleTitle | Pharmacokinetics and pharmacodynamics of NTBC (2-(2-nitro-4-fluoromethylbenzoyl)-1,3-cyclohexanedione) and mesotrione, inhibitors of 4-hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteers. | lld:pubmed |
| pubmed-article:11488774 | pubmed:affiliation | Zeneca Central Toxicology Laboratory, Alderley Park, Macclesfield, Cheshire SK10 4TJ, United Kingdom. | lld:pubmed |
| pubmed-article:11488774 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11488774 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11488774 | lld:pubmed |
